The Former Yugoslav Republic of Macedonia
Tuberculosis profile
Population  2013 2.1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.033 (0.031–0.034) 1.5 (1.5–1.6)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.52 (0.23–0.91) 25 (11–43)
Incidence  (includes HIV+TB) 0.37 (0.32–0.41) 17 (15–20)
Incidence (HIV+TB only)        
Case detection, all forms (%) 87 (77–99)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0 (0–2.2) 6.3 (0.16–30)
MDR-TB cases among notified pulmonary
TB cases
0 (0–5) 2 (0–9)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 183   23
Pulmonary, clinically diagnosed 42   1
Extrapulmonary 65   4
       
Total new and relapse 318    
Previously treated, excluding relapses 5    
Total cases notified 323    
Among 318 new and relapse cases:
23 (7%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 163 (89%) 16 (48%) 179
Laboratory-confirmed RR-/MDR-TB cases     2
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 206 (64)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 86
Previously treated cases, excluding relapse, registered in 2012 78
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 100
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.3
Culture (per 5 million population) 7.1
Drug susceptibility testing (per 5 million population) 2.4
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 1.4
% Funded domestically 8%
% Funded internationally 92%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-03 Data: www.who.int/tb/data